Shree Ganesh Remedies Q1 FY27: Profit -67%, sales -42%

Key takeaway from the June 2026 quarter

Shree Ganesh Remedies Limited reported a sharp year-on-year decline in profitability for the quarter ended June 30, 2026 (Q1 FY27), largely due to a steep fall in revenue from operations. Net profit after tax (PAT) came in at ₹1.12 crore, down 67.5% from ₹3.45 crore in the same quarter last year. Revenue from operations fell 41.8% to ₹14.36 crore from ₹24.67 crore in Q1 FY26.

The company’s operating profitability also weakened, with operating profit margin (OPM) reported at 23.33% versus 29.59% a year earlier. While the top line dropped, other income rose meaningfully and expenses declined, softening the impact on the bottom line. The results were reported as unaudited for the quarter.

Q1 FY27 financial snapshot

The decline was visible across most profitability lines. Profit before tax (PBT) fell to ₹1.53 crore from ₹4.60 crore, a drop of 66.7%. Profit before depreciation and tax (PBDT) was ₹3.97 crore compared with ₹7.02 crore.

The company also reported basic earnings per share (EPS) of ₹0.87 for Q1 FY27, down from ₹2.69 in Q1 FY26. These figures underline that the earnings contraction tracked the fall in operating revenue more than any one-off cost spike.

What changed on the income side

The main driver was lower operating revenue. Revenue from operations stood at ₹14.36 crore (₹1,436.00 lakh) in Q1 FY27 versus ₹24.67 crore (₹2,466.79 lakh) in Q1 FY26.

Other income increased 41.9% year-on-year to ₹0.94 crore (₹93.92 lakh) from ₹0.66 crore (₹66.17 lakh). This increase offered a partial offset to the weaker core business performance, helping total income for the quarter reach ₹15.30 crore.

Expenses fell, but not enough to protect profits

Total expenses for Q1 FY27 were reported at ₹13.77 crore (₹1,376.80 lakh), lower than ₹20.73 crore (₹2,073.16 lakh) in Q1 FY26. The year-on-year reduction in expenses helped cushion margins in a quarter where revenue contracted sharply.

Even with lower costs, the operating leverage effect was visible. With revenue down by about ₹10.31 crore year-on-year, the savings in expenses could not fully bridge the gap, leading to a significant decline in PBT and PAT.

Standalone and consolidated results were aligned

The report noted that consolidated financial results mirrored the standalone performance. Consolidated net profit for Q1 FY27 also stood at ₹1.12 crore. This suggests there were no material differences from consolidation adjustments for the quarter in terms of reported profitability.

Total income on a consolidated basis was ₹15.30 crore, while total expenses were ₹13.77 crore, matching the headline picture of compressed profitability but lower cost outgo versus the year-ago period.

Subsidiary update: no contribution from SGRL USA Inc.

The company’s wholly owned subsidiary, SGRL USA Inc., reported nil revenue and nil net profit for the quarter. With no operating contribution from the subsidiary during Q1 FY27, the group’s performance effectively reflected the parent company’s operating conditions.

This disclosure is relevant for investors tracking whether overseas operations are adding incremental growth or diversification to the earnings profile.

Summary table: Q1 FY27 vs Q1 FY26

Context from the previous quarter (Q4 FY26)

The quarterly trajectory looks weaker when compared with the immediately preceding quarter. For the quarter ended March 31, 2026 (Q4 FY26), Shree Ganesh Remedies reported revenue from operations of ₹33.20 crore and PAT of ₹6.27 crore. EBITDA for Q4 FY26 was reported at ₹11.37 crore, with an EBITDA margin of 34.3%.

While Q4 FY26 was described as a strong sequential recovery in the company’s audited release, Q1 FY27 reversed some of that momentum as revenue and profit fell sharply on a year-on-year comparison. The Q1 FY27 update did not provide a detailed operational explanation in the provided text beyond highlighting the revenue decline.

Market context and disclosures

A share price of ₹575.6 was cited for Shree Ganesh Remedies. The company also submitted the transcript of its Q1 FY27 earnings conference call to BSE Limited, as per the provided text. Such filings typically help investors track management commentary and clarifications around quarter performance.

Separately, the text included a statement that for FY2026-2027, revenue reached ₹112.32 crore and profit touched ₹17.76 crore. This figure is presented as stated in the source material.

Why this result matters for investors

The quarter highlights how sensitive profitability can be to swings in operating revenue, even when expenses decline. The fall in operating margin (OPM) to 23.33% from 29.59% indicates weaker conversion of sales into operating profit compared with the year-ago quarter.

With the subsidiary reporting no revenue and no profit, the operating performance remains concentrated in the core business. Investors tracking the company may focus on whether revenue normalises in subsequent quarters, and how the cost structure responds when sales are volatile.

Conclusion

Shree Ganesh Remedies posted a sharp contraction in Q1 FY27 earnings, with PAT falling to ₹1.12 crore as revenue dropped to ₹14.36 crore. Higher other income and lower expenses provided limited support, but PBT and margins still declined materially. The next set of filings and management commentary, including details from the earnings call transcript submitted to the BSE, will be important for understanding the drivers behind the revenue decline and the outlook for coming quarters.